Edison Research, page-6

With regard to Revascor (MSB/ Teva) I found it concerning that there are a number of competitors for the same indication and expecting results well before that of Revascor!

MPC-100-IM in CHF

Exhibit 5: Selected stem cell and gene therapies in Phase II or III trials for CHF Company Product Therapy class Status Target CHF patients Notes:

Mesoblast Teva Revascor Stem cell (allogeneic) Phase III-ready Ischaemic and non-ischaemic, NYHA II or III, LVEF<40 Allogeneic (bone marrow-derived) mesenchymal precursor cells (MPC). Phase III readout August 2018.

Cardio3 C-Cure Stem cell (autologous) 240-pt Phase III Ischaemic, NYHA II to IV, LVEF<30% Autologous (bone marrow-derived) cardiopoietic mesenchymal stem cells. Expected Phase III readout 2015.

Bioheart MyoCell Stem cell (autologous) 170-pt Phase II/III Ischaemic (post-AMI), NYHA II to IV, LVEF<35% Autologous (skeletal muscle-derived) myoblasts. Expected Phase II/III estimated completion February 2017.

Celladon Mydicar Gene therapy 200-pt Phase IIb Ischaemic or non-ischaemic, NHYA II to IV, LVEF<35% Gene transfer using a viral vector (AAV1) to deliver the SERCA2a gene. Expected Phase IIb readout in Q116.

Aastrom Ixmyelocel Stem cell (autologous) 108-pt Phase II Ischaemic, NYHA III or IV, LVEF<35% Autologous (bone marrow-derived) CD90+ mesenchymal cells and CD14+ monocytes. Expected Phase II readout Q315.